The underlying hypothesis of this study is that the complexity of cancer dictates that compared to single modalities, combination therapies that are mechanistically independent and which are directed at nonoverlapping molecular targets will additively or synergistically enhance treatment outcome. Toward achieving this goal, the current Program Project Grant (PPG) application builds on recent advances in the understanding of cancer biology, in mechanisms of current and emerging therapies as well as the enormous progress made in imaging technologies, to propose new photodynamic therapy (PDT)-based combination treatments for pancreato-biliary (PCBC) and non-melanoma skin cancers (NMSC) in an approach we term Combination Photodynamic Biologic Therapy (CPBT). PDT is a photochemistry-based modality that is approved for the treatment of a number of cancer and non-cancer pathologies. Strategically, these treatments response-enhancing CPBTs will be achieved in two ways: (i) by preconditioning tumors with agents which initiate molecular events that augment PDT, and (ii) by administering a second treatment specifically tailored to a particular molecular response elicited by the PDT. Optical imaging techniques will be invaluable for the online monitoring of light and photosensitizer dosimetry, treatment planning and molecular response. Project 1 will investigate molecular pathways affected by compounds that enhance ALA-PDT and can be exploited by a combination regimen to increase treatment response in skin carcinomas in models and in humans. Project 2 proposes to improve the survival and quality of life of patients with pancreatic or biliary tract carcinoma using PDT in clinical studies. Project 3 will build upon results from the previous funding cycle that PDT instigates molecular responses that can be targeted for much improved treatment outcomes. Preclinical models of pancreatic cancer (PanCa) will be used. Project 4 takes advantage of the advances in optical imaging to develop quantitative tools to monitor molecular features of tumors and their response to treatment, and to integrate them for the development of molecular-based combination therapies for standard clinical procedures. The proposed program will feature three cores that will provide support in three areas: Core A, through administration, scientific integration, education and career development, intellectual property development, and administration;Core B, through biological models, molecular pathology, and biostatistics;and Core C, through in vivo imaging, dosimetry, and the transfer of developed technologies to industry. It is anticipated that such rational, mechanism-based treatments will significantly benefit patient survival, quality of life and/or disease palliation and, combined with real-time imaging to monitor tumor progression and treatment response, provide patient-specific treatments that can be realistically envisioned. Potential benefits to public health: this program impacts on the treatment of three cancers: two of these PanCa and BTC which have few treatment options and are usually fatal. NMSC on the other hand has many options but the high incidence puts a heavy burden on society in terms of cost and suffering.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA084203-10
Application #
8403906
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Wong, Rosemary S
Project Start
1999-12-01
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2014-12-31
Support Year
10
Fiscal Year
2013
Total Cost
$1,334,595
Indirect Cost
$312,690
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Pereira, S P; Goodchild, G; Webster, G J M (2018) The endoscopist and malignant and non-malignant biliary obstruction. Biochim Biophys Acta Mol Basis Dis 1864:1478-1483
Broekgaarden, Mans; Rizvi, Imran; Bulin, Anne-Laure et al. (2018) Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Oncotarget 9:13009-13022
Huang, Huang-Chiao; Rizvi, Imran; Liu, Joyce et al. (2018) Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery. Cancer Res 78:558-571
Huang, Huang-Chiao; Pigula, Michael; Fang, Yanyan et al. (2018) Immobilization of Photo-Immunoconjugates on Nanoparticles Leads to Enhanced Light-Activated Biological Effects. Small :e1800236
Wang, Hexuan; Mislati, Reem; Ahmed, Rifat et al. (2018) Elastography can map the local inverse relationship between shear modulus and drug delivery within the pancreatic ductal adenocarcinoma microenvironment. Clin Cancer Res :
Obaid, Girgis; Jin, Wendong; Bano, Shazia et al. (2018) Nanolipid Formulations of Benzoporphyrin Derivative: Exploring the Dependence of Nanoconstruct Photophysics and Photochemistry on Their Therapeutic Index in Ovarian Cancer Cells. Photochem Photobiol :
Marra, Kayla; LaRochelle, Ethan P; Chapman, M Shane et al. (2018) Comparison of Blue and White Lamp Light with Sunlight for Daylight-Mediated, 5-ALA Photodynamic Therapy, in vivo. Photochem Photobiol 94:1049-1057
Pereira, Stephen P; Jitlal, Mark; Duggan, Marian et al. (2018) PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open 3:e000379
Maytin, Edward V; Kaw, Urvashi; Ilyas, Muneeb et al. (2018) Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: A bilaterally controlled comparison study. Photodiagnosis Photodyn Ther 22:7-13
de Souza, Ana Luiza Ribeiro; LaRochelle, Ethan; Marra, Kayla et al. (2017) Assessing daylight & low-dose rate photodynamic therapy efficacy, using biomarkers of photophysical, biochemical and biological damage metrics in situ. Photodiagnosis Photodyn Ther 20:227-233

Showing the most recent 10 out of 173 publications